Please use this identifier to cite or link to this item:
http://hdl.handle.net/10773/37402
Title: | Multicomponent and 1,3-dipolar cycloaddition synthesis of triazole- and isoxazole-acridinedione/xanthenedione heterocyclic hybrids: cytotoxic effects on human cancer cells |
Author: | Naouri, Abdelkader Djemoui, Amar Ouahrani, Mouhamad Ridha Lahrech, Mokhtar Boualem Lemouari, Najet Rocha, Djenisa H.A. Albuquerque, Hélio Mendes, Ricardo F. Almeida Paz, Filipe A. Helguero, Luisa A. Bachari, Khaldoun Talhi, Oualid Silva, Artur M.S. |
Keywords: | Click chemistry Triazole Isoxazole Acridinedione Xanthenedione Anticancer |
Issue Date: | 5-Oct-2020 |
Publisher: | Elsevier |
Abstract: | A new series of diverse 1,2,3-triazole-acridinedione/xanthenedione and 1,2-isoxazole-acridinedione/xanthenedione heterocyclic hybrids have been synthesized via 1,3-dipolar coupling reaction of N/O-substituted-acridinedione-alkyne or O-substituted-xanthenedione-alkyne substrates with various aromatic azides or oximes. In all cases, the cycloaddition is totally regioselective. The chemical structures of the synthesized compounds are determined using 2D NMR and are further confirmed by single-crystal X-ray diffraction analysis. Preliminary in vitro cytotoxic assays on two human breast cancer cell lines (MDA-MB-231, T47-D) and one prostate cancer cell line (PC3) are performed on some selected compounds. The most active O-1,2,3-triazole-xanthenedione hybrid displays the best cytotoxicity effects with IC50 ≤ 20 μM in breast cancer and IC50 = 10 μM in prostate cancer cell lines. |
Peer review: | yes |
URI: | http://hdl.handle.net/10773/37402 |
DOI: | 10.1016/j.molstruc.2020.128325 |
ISSN: | 0022-2860 |
Appears in Collections: | CICECO - Artigos IBIMED - Artigos DQ - Artigos QOPNA - Artigos DCM - Artigos REQUIMTE - Artigos |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Multicomponent and 1,3-dipolar cycloaddition synthesis of triazole.pdf | 1.85 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.